Array BioPharma, 3200 Walnut Street, Boulder, CO 80301, United States.
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6237-41. doi: 10.1016/j.bmcl.2012.08.007. Epub 2012 Aug 10.
Cell potent inhibitors of B-Raf(V600E) that bind to the kinase in the DFG-out conformation are reported. These compounds utilize the hinge-binding group and lipophilic linker from a previously disclosed series of B-Raf(V600E) inhibitors that bind to the kinase in an atypical DFG-in, αC-helix-out conformation. This new series demonstrates that DFG-out kinase inhibitors can be rationally designed from related inhibitors which utilize an unconventional binding mode. Kinase selectivity profiles are compared. The pattern of kinase selectivity was found to be determined by the feature of the inhibitor which extends into the back pocket of the kinase and leads to the kinase conformation, rather than by the hinge-binding group or other minor modifications.
报道了一类能够与处于 DFG-out 构象的 B-Raf(V600E)激酶结合的细胞有效抑制剂。这些化合物利用了先前报道的一系列 B-Raf(V600E)抑制剂中的 hinge 结合基团和脂环 linker,这些抑制剂以非典型的 DFG-in,αC-helix-out 构象与激酶结合。这一系列新的抑制剂证明,DFG-out 激酶抑制剂可以通过利用非传统结合模式的相关抑制剂进行合理设计。比较了激酶选择性概况。发现激酶选择性模式取决于抑制剂的特征,该特征延伸到激酶的后袋并导致激酶构象,而不是 hinge 结合基团或其他较小的修饰。